Suboptimal awareness and comprehension of published preexposure prophylaxis efficacy results among physicians in Massachusetts

AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV

Volumn 26, Issue 6, 2014, Pages 684-693

  Mimiaga, Matthew J ^a,b,c   White, Jaclyn M ^c   Krakower, Douglas S ^d   Biello, Katie B ^b,c   Mayer, Kenneth H ^c,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c FENWAY INSTITUTE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

HIV; physicians; preexposure prophylaxis; PrEP; prevention

Indexed keywords

EMTRICITABINE; TENOFOVIR;

ADULT; ARTICLE; AWARENESS; CLINICAL EFFECTIVENESS; COITUS; COMPREHENSION; DRUG EFFICACY; FEMALE; GEL; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; PATIENT SAFETY; PHYSICIAN; PILL; PREEXPOSURE PROPHYLAXIS; PRESCRIPTION; PRIORITY JOURNAL; PROPHYLAXIS; PUBLICATION; RESOURCE ALLOCATION; TRANSACTIONAL SEX; UNITED STATES;

ADULT; AGED; ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HIV INFECTIONS; HUMANS; INTERNET; INTERVIEWS AS TOPIC; MALE; MASSACHUSETTS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHYSICIANS; QUESTIONNAIRES; SOCIOECONOMIC FACTORS;

EID: 84895525254     PISSN: 09540121     EISSN: 13600451     Source Type: Journal    
DOI: 10.1080/09540121.2013.845289     Document Type: Article

References (25)

1. Abdool Karim, Q., Abdool Karim, S. S., Frohlich, J. A., Grobler, A. C., Baxter, C., & Mansoor, L. E. (2010). Effectiveness and safety of Tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science, 329, 1168-1174. doi:10.1126/science.1193748
2. AIDS Healthcare Foundation. (2012). FDA AIDS protest targets approval of Gilead's prevention pill. Retrieved from http://www.aidshealth.org/archives/6488
3. Ajzen, I., & Madden, T. J. (1986). Prediction of goal-directed behavior: Attitudes, intentions, and perceived behavioral control. Journal of Experimental Social Psychology, 22, 453-474. doi:10.1016/0022-1031(86)90045-4
4. Arnold, E. A., Hazelton, P., Lane, T., Christopoulos, K. A., Galindo, G. R., & Steward, W. T. (2012). A qualitative study of provider thoughts on implementing pre-exposure prophylaxis (PrEP) in clinical settings to prevent HIV infection. PLoS ONE, 7, e40603. doi:10.1371/journal. pone.0040603
5. Associated Press. (2012). FDA panel backs first pill to block HIV infection. Retrieved from http://www.msnbc.msn.com/id/47386249/ns/health-aids/t/ fda-panel-backs-first-pill-blockhiv-infection/#.UNzDCazheSo
6. Baeten, J., & Celum, C. (2012). Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. The New England Journal of Medicine, 367, 399-410. doi:10.1056/NEJMoa1108524
7. Bernstein, K. T., Liu, K., Begier, E. M., Koblin, B., Karpati, A., & Murrill, C. (2008). Same-sex attraction disclosure to health care providers among New York City men who have sex with men: Implications for HIV testing approaches. Archives of Internal Medicine, 168, 1458-1464. doi:10.1001/archinte. 168.13.1458
8. Boldero, J., Sanitioso, R., & Brain, B. (1999). Gay Asian Australians' safer-sex behavior and behavioral skills: The predictive utility of the theory of planned behavior and cultural factors 1. Journal of Applied Social Psychology, 29, 2143-2163. doi:10.1111/j.1559-1816.1999.tb02299.x
9. Centers for Disease Control and Prevention (CDC). (2012a). CDC statement on FDA approval of drug for HIV prevention. Retrieved from http://www.cdc.gov/ hiv/prep/pdf/CDC-FDA-Approval-Truvada.pdf
10. Centers for Disease Control and Prevention (CDC). (2012b). CDC statement on FDA approval of drug for HIV prevention (Press Release). Retrieved from http://www.cdc.gov/hiv/prep/pdf/CDC-FDA-Approval-Truvada.pdf
11. DeVellis, R. F. (2003). Scale development: Theory and applications. Thousand Oaks, CA: Sage.
12. Epstein, R. M., Morse, D. S., Frankel, R. M., Frarcy, L., Anderson, K., & Beckman, H. B. (1998). Awkward moments in patient-physician communication about HIV risk (Vol. 128). Philadelphia, PA: American College of Physicians.
13. Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., ⋯ Glidden, D. V. (2010). Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. The New England Journal of Medicine, 363, 2587-2599. doi:10.1056/NEJMoa1011205
14. Hall, H. I., Song, R., Rhodes, P., Prejean, J., An, Q., & Lee, L. M. (2008). HIV incidence surveillance group: Estimation of HIV incidence in the United States. Journal of the American Medical Association, 300, 520-529. doi:10.1001/jama.300.5.520
15. Jolliffe, I. T. (2002). Principal components analysis. New York, NY:Springer.
16. Maznavi, K., Hardy, D., & Bredeek, F. (2011). Pre-exposure prophylaxis (PrEP) for HIV: An online survey of HIV healthcare providers evaluating their knowledge, perception, and prescription of PrEP [409]. 49th Annual Meeting of the Infectious Diseases Society of America, Boston.
17. Mutua, G., Sanders, E., Mugo, P., Anzala, O., Haberer, J. E., & Bangsberg, D. (2012). Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. PLoS ONE, 7, e33103. doi:10.1371/journal.pone.0033103
18. Paltiel, A. D., Freedberg, K. A., Scott, C. A., Schackman, B. R., Losina, E., & Wang, B. (2009). HIV preexposure prophylaxis in the United States: Impact on lifetimeinfection risk, clinical outcomes, and cost-effectiveness. Clinical Infectious Diseases, 48, 806-815. doi:10.1086/597095
19. Petroll, A. E., & Mosack, K. E. (2011). Physician awareness of sexual orientation and preventive health recommendations to men who have sex with men. Sexually Transmitted Diseases, 38(1), 63-67. doi:10.1097/OLQ.0b013e3181 ebd50f
20. Supervie, V., García-Lerma, J. G., Heneine, W., & Blower, S. (2010). HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis. Proceedings of the National Academy of Sciences, 107, 12381-12386. doi:10.1073/pnas.1006061107
21. Susman, E. (2012). Prophylaxis fails to prevent HIV in women. Retrieved from http://www.medpagetoday.com/Meeting-Coverage/CROI/31506
22. Tripathi, A., Ogbuanu, C., Monger, M., Gibson, J. J., & Duffus, W. A. (2012). Pre-exposure prophylaxis for HIV infection: Healthcare providers' knowledge, perception, and willingness to adopt future implementation in the Southern US. Southern Medical Journal, 105(4), 8. doi:10.1097/SMJ. 0b013e31824f1a1b
23. Tuller, D. (2011). Questions on tactic to prevent HIV. Retrieved from http://www.nytimes.com/2011/10/11/health/11hiv.html?pagewanted=all&-r=1&
24. Underhill, K., Operario, D., Skeer, M. R., Mimiaga, M. J., & Mayer, K. H. (2010). Packaging PrEP to prevent HIV: An integrated framework to plan for pre-exposure prophylaxis implementation in clinical practice. Journal of Acquired Immune Deficiency Syndromes 55(1), 8-13. doi:10.1097/QAI. 0b013e3181e8efe4
25. White, J. M., Mimiaga, M. M., Krakower, D. S., & Mayer, K. M. (2012). Evolution of Massachusetts physician attitudes, knowledge, and experience regarding the use of antiretrovirals for HIV prevention. AIDS Patient Care STDS, 26, 395-405.